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Abstract
Isolated tricuspid valve surgery is usually carried out with very high morbidity
and mortality given the complexity of the affected patients. In light of this,
trans-catheter tricuspid valve interventions have been emerging as an attractive
alternative to surgery over the last few years. Although feasibility has been
shown with a number of devices, clinical experience remains preliminary and
associated with significant clinical and technical challenges. Here we describe
currently available trans-catheter treatment options for severe tricuspid
regurgitation implanted in different locations.
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Introduction
Tricuspid valve insufficiency is reported as the most common 
valvular heart disease, affecting 65 to 85% of the population1; 
the true prevalence of moderate or severe tricuspid regurgita-
tion (TR) has been estimated at 1.6 million people in the United 
States2. Despite this prevalence and its known association 
with mortality3, the tricuspid was considered as the “forgotten 
valve” until recently for two main reasons. Firstly, symptoms 
resulting from TR may be uncertain, particularly in the early 
stages of the disease, leading to a late referral. Secondly, once 
right ventricular dysfunction develops, the patient is consid-
ered end-stage. Moreover, functional TR frequently coexists 
with left-sided valve disease (LVD), but avoidance of con-
comitant tricuspid valve repair was accepted based on the 
incorrect assumption that TR would improve once the primary 
LVD had been treated4.
When untreated, TR commonly progresses to right ventricular 
failure, with the associated impact on the patient’s prognosis 
and quality of life. In the subgroup with advanced disease, 
the indication for treatment remains more challenging given 
the complexity of the patients and the significant risk of 30-day 
mortality5.
Recently, the assessment and management of tricuspid valve 
disease have developed because of the increasing body of evi-
dence regarding the adverse impact of severe TR and the recent 
advances in surgical and percutaneous trans-catheter tech-
niques. In the current European guidelines, the indication for 
surgery for severe TR is now generally accepted (class I). With 
regard to treatment in lesser degrees of TR, there is a trend 
for intervention, especially during surgery for left heart valve 
disease and/or in cases of significant dilatation of the tricuspid 
annulus (class IIa). In addition, after previous left-sided valve 
surgery and in the absence of recurrent left-sided valve dys-
function, surgery may be considered in patients with severe 
TR who are symptomatic or have progressive right ventricular 
dilatation/dysfunction in the absence of severe right ventricular 
or left ventricular dysfunction and/or severe pulmonary vas-
cular disease/hypertension6. This more aggressive approach to 
TR after previous left-sided valve surgery may result in dealing 
with fewer end-stage patients who could benefit from the 
treatment.
Despite recent progress in the understanding of this com-
plex pathology and the attempt to treat these patients at the 
earliest possible stage, the majority remain a high-risk popu-
lation affected by severe TR, right ventricular dysfunction, 
and multiple comorbidities. In view of the above, different 
trans-catheter tricuspid valve therapies are emerging.
Challenging anatomical features for trans-catheter 
therapies
The anatomy of the tricuspid valve apparatus appears to be more 
complex than the mitral valve. It is variable in terms of number, 
size, and attachment of the papillary muscle and, in contrast 
to the mitral valve, tricuspid valve chordae may attach directly 
to the right ventricular endocardium.
The tricuspid annulus is an ellipsoid nonplanar structure with 
a saddle-shaped conformation that becomes more circular as 
it dilates in an anterior-posterior direction in response to right 
ventricular enlargement, which is also a dynamic structure 
that modifies its dimension and shape during the cardiac cycle7.
Several aspects represent a challenge for percutaneous therapy. 
The tricuspid orifice is larger, more triangular, and more frag-
ile than the mitral one; in addition, the lack of calcium observed 
in secondary TR represents an anchorage-complicating factor.
The tricuspid annulus has significant anatomical relationships 
with the right coronary artery, the coronary sinus, the aortic 
valve, and the atrio-ventricular node. All of these structures can 
be damaged during trans-catheter procedures.
The angulation between both venae cavae and the tricuspid 
annulus should be taken into consideration in the conception of 
a delivery system for percutaneous approach; alternatively, if 
considering a trans-apical approach, the thin apical wall and the 
presence of multiple chordae render this approach very difficult8.
Finally, in a considerable portion of patients, the secondary TR 
is due to the presence of pacemaker or defibrillator leads9 that 
represent a limitation in applying percutaneous techniques.
Multi-modal imaging to plan trans-catheter therapies
Quantification of the severity of TR has been well described 
by the European Association of Echocardiography guide-
lines, clearly defining qualitative and quantitative parameters10. 
Moreover, considering the last guidelines of the European 
Society of Cardiology, the measurement of the septo-lateral 
dimension of the tricuspid annulus to identify significant annu-
lar dilatation (diastolic dimension ≥40 mm or >21 mm/m2) is 
important, as it supports intervention11.
To perform a first evaluation, a trans-thoracic echocardiogram 
is enough, but, to correctly plan a percutaneous intervention, a 
multi-modal imaging approach is mandatory. Three-dimensional 
trans-esophageal echocardiogram has significantly improved 
the accuracy of tricuspid valve apparatus imaging, giving 
adjunctive information on its anatomic components and 
highlighting the lesions liable for the mechanism of regurgitation. 
A standardization of imaging projections has been proposed 
by Lang et al.12 to obtain an en face view of the tricuspid valve, 
improving communication with the interventionist.
Pre-procedural planning using multi-detector computed tom-
ography (MDCT) provides many details regarding tricuspid 
annulus measurement, the relationship with the surrounding 
structures, and good-quality motion-free images of the right 
ventricular outflow tracts13. Furthermore, MDCT is used to access 
routes for percutaneous procedures.
Applying this multi-modal imaging approach is crucial to obtain 
essential information to correctly choose the proper trans-catheter 
technique.
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Trans-catheter therapies for tricuspid regurgitation
Given the considerable surgical risk of tricuspid valve surgery 
for severe TR, especially in the reoperation scenario, there has 
been a progressive development of percutaneous trans-catheter 
techniques in the last few years. Anatomical aspects, such as 
the non-planar and large tricuspid annulus, absence of calcium, 
right ventricular geometry, and approximation of critical 
surrounding structures, have to be taken into consideration and 
make this procedure very challenging14.
The Gate™ Tricuspid Valved Stent (Navigate Cardiac Struc-
ture Inc.) is the first prosthesis implanted in the tricuspid posi-
tion using a trans-jugular or trans-atrial mode of access and has 
been implanted successfully in two patients15. As an alterna-
tive to trans-catheter tricuspid valve implantation, four kinds 
of percutaneous therapies have recently emerged to treat 
severe tricuspid valve regurgitation: trans-catheter heterotopic 
implant of valve into the vena cava, trans-catheter annuloplasty, 
trans-catheter edge-to-edge repair, and trans-catheter implant 
of a device dedicated to improve leaflet coaptation.
Heterotopic caval trans-catheter valve implantation
Caval valve implantation (CAVI) has been proposed to address 
the reflux of severe TR into both venae with the purpose of 
effectively improving the symptoms of right ventricular fail-
ure. The main anatomical challenges in applying this specific 
technique is the large and variable diameter of the inferior 
and superior vena cava, especially in the presence of chronic 
severe TR, and the length of the landing zone with respect to the 
inferior vena cava (IVC) and the closeness to the hepatic veins.
Clinical experience started in 2011, with the first reported com-
passionate case of CAVI using two custom-made self-expand-
able valves16. Since then, compassionate cases confirmed the 
feasibility of this technique and the immediate hemodynamic 
improvement17. In light of this, two valve prototypes, the self-
expandable TricValve (P+F Products + Features Vertriebs GmbH, 
Vienna, Austria, in cooperation with Braile Biomedica, São 
José do Rio Preto, Brazil) and the balloon-expandable Edwards 
valve (Edwards Lifesciences, Irvine, CA, USA), have been tested 
in proof-of-concept trials.
The TricValve consists of two self-expandable bioprosthetic 
valves covering sizes from 28 to 43 mm for both caval veins. 
This device does not require pre-stenting of the cavae to permit 
its implant. The prosthetic valve conceived for the IVC has the 
upper segment protruding into the right atrium to avoid any dan-
gerous interaction with hepatic veins. The device designed for 
the superior vena cava is mounted on a funnel-shaped stent 
frame to allow its release at the level of the cavo–atrial junction. 
The procedure is guided by fluoroscopy, and echocardiography 
is used for post-interventional control.
Concerning the heterotopic caval implantation of 29 mm 
balloon-expandable Edwards SAPIEN XT or SAPIEN 3 valves, 
it has been performed off-label for patients at prohibitive 
surgery risk. To consider a safe implantation of this prosthesis, a 
self-expandable stent was implanted at the level of the cavo–atrial 
junction to create a landing zone for valve anchoring. Ten 
compassionate cases have been performed, but, although the 
implant was successfully achieved in all patients without 
peri-procedural complications, the 9-month follow-up mortality 
was 90%18.
Trans-catheter tricuspid valve annuloplasty
Severe functional TR is due to a significant annular dilatation, 
and that is why surgical annuloplasty is the first procedure of 
choice in treating this condition. Applying this principle to the 
percutaneous techniques results in several complexities. Unlike 
its left counterpart, the tricuspid annulus is not prominent or 
fibrous and for this reason does not ensure proper stability 
for safely anchoring some devices. Moreover, the highly indi-
vidual shape of the valve adds complexity. Finally, several 
crucial structures are closely related to the tricuspid annulus and 
are at risk of injury.
The Trialign device (Mitralign, Inc. Tewksbury, MA, USA) 
mimics the Kay surgical procedure consisting of plication 
of the tricuspid annulus at the level of the posterior leaflet19. 
The operator performs a trans-catheter bicuspidization of the 
tricuspid valve through a trans-venous jugular approach, implant-
ing one or multiple pairs of pledgets. Once implanted, the 
pledgeted sutures are brought together to obtain plica-
tion of the annulus. The first-in-human experience with this 
system has been reported, demonstrating the feasibility of this 
procedure and resulting in a reduction of the tricuspid annular 
dimensions20.
The safety and feasibility of this device has been tested in the 
SCOUT I feasibility trial, which included 15 patients with 
severe TR who underwent tricuspid annuloplasty with the Tria-
lign. The device was successfully implanted in all cases, with 
only one procedural complication (new right coronary stenosis 
requiring coronary stenting). At 30-day follow-up, survival 
was 100%, with a technical success rate of 80% (three single 
pledget dehiscence). No major adverse events were observed. 
A significant reduction in the tricuspid annular area, as well 
as an improvement in functional class and quality of life, 
was maintained for up to 6 months21.
The TriCinch system (4Tech Cardio, Galway, Ireland) is a 
percutaneous annuloplasty device designed to cinch the tricuspid 
annulus, improving leaflet coaptation and reducing TR22. 
Through a transfemoral mode of access, a corkscrew element 
is implanted in the anterior tricuspid annulus. Once the cork-
screw is secured, the system is retrieved and a self-expandable 
nitinol stent is introduced over the wire and coupled to the 
implant. The whole system is then tensioned to reshape the 
tricuspid valve and to increase the leaflet coaptation under 
live echo guidance. Finally, the stent is deployed in the IVC to 
maintain the tension applied. The first-in-human implanta-
tion of this device has been reported23. The device is currently 
being evaluated in an ongoing feasibility trial, the PREVENT 
study (Percutaneous Treatment of Tricuspid Valve Regurgita-
tion with the TriCinch System; NCT02098200) with the purpose 
of demonstrating immediate and post-operative safety and 
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efficacy in TR reduction (≥1 grade) in 24 patients. A second- 
generation device with improved durability is currently under 
preliminary clinical evaluation. The first-in-man patient has 
been recently successfully treated24.
The Cardioband system (Edwards Lifescience, Irvine, CA, 
USA) is a suture-less and adjustable surgical-like Dacron band 
that mimics the effects of undersized annuloplasty (Figure 1). It 
consists of a three-step approach: implant deployment, anchor 
implantation, and size adjustment. A percutaneous transfemo-
ral approach is used and the device is implanted on the atrial 
side of the tricuspid annulus by means of multiple anchor ele-
ments. After the implant, the size of the device can be reduced 
in a reversible fashion in order to reduce the annular dimen-
sion and increase leaflet coaptation. Preliminary results from 
the early feasibility trial in the tricuspid position have been 
recently presented25. Among 20 patients with severe functional 
TR treated so far, a 27% reduction of septo-lateral tricuspid 
annular dimension has been reported. At 30 days, core-lab 
adjudicated data (available for a minority of patients) 
showed a reduction of TR, with a significant improvement 
in symptoms and quality of life.
The Millipede system (Millipede, LLC, Ann Arbor, MI, USA) 
is a fully repositionable and retrievable complete ring, which 
can be implanted surgically or in a trans-catheter fashion on 
the atrial side of the native tricuspid annulus in order to restore 
its shape and diameter. So far, only two patients have received 
a tricuspid implant under direct surgical vision, showing 
tricuspid diameter reductions of 42–45%, with no post-procedural 
residual TR26.
Trans-catheter edge-to-edge repair
The MitraClip® device (Abbott Vascular, Santa Clara, CA, 
USA) consists of a 4 mm wide cobalt-chromium, polyester- 
covered implant with two arms that are opened and closed by 
control mechanisms on the clip delivery system (Figure 2). 
During the last few years, the MitraClip® has become an 
attractive trans-catheter alternative to treat selected patients 
affected by severe mitral regurgitation and recently has been 
used successfully for treating severe TR in very high-risk 
patients27. The transfemoral access has become the preferred 
route of access today. Nickenig et al. recently reported promis-
ing 30-day outcomes in a series of 64 high-risk patients with 
severe functional TR treated with tricuspid clipping. A 
significant reduction in TR and clinical improvements were 
observed28.
Coaptation device
The FORMA Repair System (Edwards Lifesciences, Irvine, 
CA, USA) acts as a coaptation device with the purpose of 
reducing the TR grade in patients with severe TR. It is com-
posed of a spacer, which is positioned into the regurgitant 
orifice, creating a platform for the native leaflet to coapt, and a 
rail anchored at the right ventricular apex, which ensures device 
fixation. The spacer consists of a foam-filled polymer balloon 
available in two sizes (12 and 15 mm). Introduced through venous 
subclavian access, after the final positioning, it is proximally 
Figure 1. Intra-procedural imaging of the Cardioband system 
(Edwards Lifescience, Irvine, CA, USA).
Figure 2. Intra-procedural imaging of the MitraClip® device 
(Abbott Vascular, Santa Clara, CA, USA).
locked at the subclavian region.
To date, seven patients treated with this device have been 
reported29. Initial first-in-man experience shows that the device 
was correctly implanted in all patients without any complica-
tion. There was no in-hospital mortality, and all of the treated 
patients completed 30-day follow-up without further evidence 
of device-related complication. A reduction in the severity of 
TR was observed in all patients as assessed by transthoracic 
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echocardiography. This change in TR was associated with a 
significant improvement in New York Heart Association (NYHA) 
functional classification, accompanied by relevant reductions 
in peripheral edema in all patients. The clinical outcomes (up 
to 1 year) of the first 18 patients have been reported recently30. 
Acute TR reduction of at least one grade was achieved in 89% 
patients, with an extremely low incidence of adverse events. 
Significant improvements in functional status and reverse 
remodeling of the RV were observed at follow-up. An early 
feasibility trial is currently ongoing in the United States 
(NCT02471807).
Results
All of the above-mentioned percutaneous techniques have 
emerged during the last few years with the purpose of treating 
patients with severe symptomatic functional TR, who conven-
tionally represent a high-risk surgical population. Most of the 
patients percutaneously treated today are affected by end-stage 
heart failure, with right ventricular dysfunction and severe comor-
bidities, and these therapeutic options are offered in a compas-
sionate treatment scenario. In light of this, assessing the real 
clinical benefits of trans-catheter tricuspid valve therapies 
remains extremely difficult, as well as identifying which patients 
may benefit from an interventional treatment.
In order to address these issues, the first international registry 
for trans-catheter tricuspid valve therapies (the international 
multicenter TriValve registry) was established to collect data 
regarding patients undergoing tricuspid valve interventions 
with currently available devices31. To date, the TriValve registry 
has data from 106 patients with severe TR from 11 cardiac cent-
ers. Functional TR was present in 95.2% of patients, with a 
mean tricuspid annulus of 45.4 ± 11 mm. In 56.3% of patients, 
there was right ventricular dysfunction defined as TAPSE <17 
mm and 95% of the entire cohort were in NYHA functional 
class III to IV. A total of 35% of patients had prior left heart 
valve intervention.
A total of 55% of patients (n = 58) were treated by MitraClip, 
16% by Trialign (n = 17), 14% by TriCinch (n = 15), 7% by 
FORMA (n = 7), 5% by Cardioband (n = 5), and 3% of patients 
(n = 3) underwent CAVI. No differences in terms of EURO-Score 
II and degree of right ventricular dysfunction were observed 
between the patients treated with the different techniques.
Procedural success was achieved in 62% of cases. At 30-day 
follow-up, all-cause mortality was 3.7%, with an overall 
incidence of major adverse cardiac and cerebrovascular events 
of 26%; 58% of patients were NYHA functional class I or II at 
30 days. The dosage of diuretics was significantly reduced at 
follow-up compared to baseline, as was the degree of TR 
(≤2+ in 49% of patients).
These initial results showed that the multiple percutaneous 
devices available for the treatment of TR are being utilized in 
patients at high surgical risk with early clinical efficacy, but 
further studies are necessary to better define optimal patient 
selection, timing of intervention, disease severity, and device 
efficacy31.
Reporting outcomes after trans-catheter tricuspid 
valve therapies: towards T-VARC
The analysis of preliminary results from the early feasibility 
trials with the different devices raises the issue of how to report 
outcomes after trans-catheter tricuspid valve therapies. Patients 
consistently report improvements in quality of life measures 
despite only modest reductions in TR, according to the 
conventional definitions. Given the discordance between TR 
reduction and clinical improvement, it is evident that we cannot 
use the definitions of procedural success for the tricuspid valve 
that are used for aortic and mitral valves. This observation 
raises the need to define appropriate outcomes in this 
patient population and develop standard definitions on how 
to evaluate and report outcomes.
Competing interests
The authors declare that they have no competing interests.
Grant information
The author(s) declared that no grants were involved in supporting 
this work.
References F1000 recommended
1. Singh JP, Evans JC, Levy D, et al.: Prevalence and clinical determinants of 
mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study).  
Am J Cardiol. 1999; 83(6): 897–902.  
PubMed Abstract | Publisher Full Text 
2. Stuge O, Liddicoat J: Emerging opportunities for cardiac surgeons within 
structural heart disease. J Thorac Cardiovasc Surg. 2006; 132(6): 1258–61. 
PubMed Abstract | Publisher Full Text 
3.  Nath J, Foster E, Heidenreich PA: Impact of tricuspid regurgitation on long-
term survival. J Am Coll Cardiol. 2004; 43(3): 405–9.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
4. De Bonis M, Taramasso M, Lapenna E, et al.: Management of tricuspid 
regurgitation. F1000Prime Rep. 2014; 6: 58.  
PubMed Abstract | Publisher Full Text | Free Full Text 
5.  Leviner DB, Medalion B, Baruch I, et al.: Tricuspid valve replacement: the 
effect of gender on operative results. J Heart Valve Dis. 2014; 23(2): 209–15.  
PubMed Abstract | F1000 Recommendation 
6. Buzzatti N, Iaci G, Taramasso M, et al.: Long-term outcomes of tricuspid valve 
replacement after previous left-side heart surgery. Eur J Cardiothorac Surg. 
2014; 46(4): 713–9; discussion 719.  
PubMed Abstract | Publisher Full Text 
7. Rodés-Cabau J, Taramasso M, O'Gara PT: Diagnosis and treatment of tricuspid 
valve disease: current and future perspectives. Lancet. 2016; 388(10058): 2431–
42. PubMed Abstract | Publisher Full Text 
8. Taramasso M, Vanermen H, Maisano F, et al.: The growing clinical importance 
of secondary tricuspid regurgitation. J Am Coll Cardiol. 2012; 59(8): 703–10. 
PubMed Abstract | Publisher Full Text 
Page 6 of 8
F1000Research 2018, 7(F1000 Faculty Rev):355 Last updated: 22 MAR 2018
9. Kim JB, Spevack DM, Tunick PA, et al.: The effect of transvenous pacemaker 
and implantable cardioverter defibrillator lead placement on tricuspid valve 
function: an observational study. J Am Soc Echocardiogr. 2008; 21(3): 284–7. 
PubMed Abstract | Publisher Full Text 
10. Lancellotti P, Moura L, Pierard LA, et al.: European Association of 
Echocardiography recommendations for the assessment of valvular 
regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease). 
Eur J Echocardiogr. 2010; 11(4): 307–32.  
PubMed Abstract | Publisher Full Text 
11.  Baumgartner H, Falk V, Bax JJ, et al.: 2017 ESC/EACTS Guidelines for the 
management of valvular heart disease. Eur Heart J. 2017; 38(36): 2739–91. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
12.  Lang RM, Badano LP, Tsang W, et al.: EAE/ASE recommendations for 
image acquisition and display using three-dimensional echocardiography.  
J Am Soc Echocardiogr. 2012; 25(1): 3–46.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
13.  Saremi F, Hassani C, Millan-Nunez V, et al.: Imaging Evaluation of Tricuspid 
Valve: Analysis of Morphology and Function With CT and MRI. AJR Am J 
Roentgenol. 2015; 204(5): W531–42.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
14.  Rodés-Cabau J, Hahn RT, Latib A, et al.: Transcatheter Therapies for 
Treating Tricuspid Regurgitation. J Am Coll Cardiol. 2016; 67(15): 1829–45.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
15. https://www.navigatecsi.com/technology
16. Lauten A, Ferrari M, Hekmat K, et al.: Heterotopic transcatheter tricuspid 
valve implantation: first-in-man application of a novel approach to tricuspid 
regurgitation. Eur Heart J. 2011; 32(10): 1207–13.  
PubMed Abstract | Publisher Full Text | Free Full Text 
17.  Lauten A, Doenst T, Hamadanchi A, et al.: Percutaneous bicaval valve 
implantation for transcatheter treatment of tricuspid regurgitation: clinical 
observations and 12-month follow-up. Circ Cardiovasc Interv. 2014; 7(2): 268–72. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
18.  Laule M, Stangl V, Sanad W, et al.: Percutaneous transfemoral management 
of severe secondary tricuspid regurgitation with Edwards Sapien XT 
bioprosthesis: first-in-man experience. J Am Coll Cardiol. 2013; 61(18): 1929–31. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
19. Kay JH, Maselli-Campagna G, Tsuji KK: Surgical Treatment of Tricuspid 
Insufficiency. Ann Surg. 1965; 162(1): 53–8.  
PubMed Abstract | Free Full Text 
20.  Schofer J, Bijuklic K, Tiburtius C, et al.: First-in-human transcatheter 
tricuspid valve repair in a patient with severely regurgitant tricuspid valve.  
J Am Coll Cardiol. 2015; 65(12): 1190–5.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
21.  Hahn RT, Meduri CU, Davidson CJ, et al.: Early Feasibility Study of a 
Transcatheter Tricuspid Valve Annuloplasty: SCOUT Trial 30-Day Results.  
J Am Coll Cardiol. 2017; 69(14): 1795–806.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
22. Taramasso M, Latib A, Denti P, et al.: Percutaneous repair of the tricuspid valve 
using a novel cinching device: acute and chronic experience in a preclinical 
large animal model. EuroIntervention. 2016; 12(7): 918–25.  
PubMed Abstract | Publisher Full Text 
23. Latib A, Agricola E, Pozzoli A, et al.: First-in-Man Implantation of a Tricuspid 
Annular Remodeling Device for Functional Tricuspid Regurgitation. JACC 
Cardiovasc Interv. 2015; 8(13): e211–4.  
PubMed Abstract | Publisher Full Text 
24. Denti P: EuroPCR 2017, Paris. 
25. Kuck KH: EuroPCR 2017, Paris. 
26. Rogers J: TVT 2017, Chicago. 
27.  Braun D, Nabauer M, Orban M, et al.: Transcatheter treatment of 
severe tricuspid regurgitation using the edge-to-edge repair technique. 
EuroIntervention. 2017; 12(15): e1837–e1844.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
28. Nickenig G, Kowalski M, Hausleiter J, et al.: Transcatheter Treatment of Severe 
Tricuspid Regurgitation With the Edge-to-Edge MitraClip Technique. Circulation. 
2017; 135(19): 1802–14.  
PubMed Abstract | Publisher Full Text 
29.  Campelo-Parada F, Perlman G, Philippon F, et al.: First-in-Man Experience 
of a Novel Transcatheter Repair System for Treating Severe Tricuspid 
Regurgitation. J Am Coll Cardiol. 2015; 66(22): 2475–83.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
30. Perlman G: EuroPCR. 2017, Paris.
31. Taramasso M, Hahn RT, Alessandrini H, et al.: The International Multicenter 
TriValve Registry: Which Patients Are Undergoing Transcatheter Tricuspid 
Repair? JACC Cardiovasc Interv. 2017; 10(19): 1982–90.  
PubMed Abstract | Publisher Full Text 
Page 7 of 8
F1000Research 2018, 7(F1000 Faculty Rev):355 Last updated: 22 MAR 2018
 Open Peer Review
   Current Referee Status:
Editorial Note on the Review Process
 are commissioned from members of the prestigious   and are edited as aF1000 Faculty Reviews F1000 Faculty
service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees
provide input before publication and only the final, revised version is published. The referees who approved the
final version are listed with their names and affiliations but without their reports on earlier versions (any comments
will already have been addressed in the published version).
The referees who approved this article are:
Version 1
The benefits of publishing with F1000Research:
Your article is published within days, with no editorial bias
You can publish traditional articles, null/negative results, case reports, data notes and more
The peer review process is transparent and collaborative
Your article is indexed in PubMed after passing peer review
Dedicated customer support at every stage
For pre-submission enquiries, contact   research@f1000.com
 Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua,Luigi Paolo Badano
Italy
 No competing interests were disclosed.Competing Interests:
1
 Department of Cardiothoracic Surgery, Leiden University Medical Center, Leiden,Meindert Palmen
Netherlands
 No competing interests were disclosed.Competing Interests:
1
 Department of Congenital Cardiology and Cardiac Surgery, IRCCS Policlinico SanGianfranco Butera
Donato, San Donato Milanese, Italy
 No competing interests were disclosed.Competing Interests:
1
Page 8 of 8
F1000Research 2018, 7(F1000 Faculty Rev):355 Last updated: 22 MAR 2018
